Nucleix

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases.

Nucleix has raised $88.3M in total funding across 5 rounds. The company is currently at the C stage. Key investors include Sands Capital, RA Capital Management, OrbiMed.

Nucleix was founded in 2008 by Adam Wasserstrom (Co- Founder & VP Bioinformatics), Danny Frumkin (Co-founder & VP Research).

Nucleix operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Test Diagnostics & Screening, with core technologies in Artificial Intelligence, Machine Learning, Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Healthcare, Providers, Patients, Laboratories.

Nucleix is based in Prof. Haim Pekeris Street 3, Rehovot, Israel, Center District. The company also has offices abroad.